A cost-effective alternative product for gingival regeneration
Active Grant Awarded
- Award ID
- R41DE035779
- Recipient
-
Preserver TECH LLC UEI NSZ7HK36TVX7
- Awarding agency
-
National Institute of Dental and Craniofacial Research
National Institutes of Health, Department of Health and Human Services
- Obligated
- $306,872
Award facts
- Assistance listing
- 93.121 Oral Diseases and Disorders Research
- Completion date 19% complete
- Place of performance
- Milwaukee, WI 53233, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services National Institutes of Health National Institute of Dental and Craniofacial Research awarded Grant R41DE035779 to Preserver TECH LLC (UEI NSZ7HK36TVX7) on September 14, 2026, with $306,872 obligated under the Oral Diseases and Disorders Research program (CFDA 93.121). The award funds development of MUCOREGEN, a cost-effective gelatin-based matrix product for gingival tissue regeneration, positioned as an alternative to invasive autologous free gingival and connective tissue grafts and to commercial products such as Mucograft, AlloDerm, and Novomatrix. The product uses a dual-porosity scaffold with interconnected macro- and micropores that the proposal describes as closely mimicking native extracellular matrix. The proposed Phase I study will include comprehensive in vitro work. Preliminary results cited in the proposal report over a threefold increase in cell proliferation compared with conventional scaffolds, and pilot in vivo performance comparable to autologous grafts and slightly greater than Mucograft in increasing keratinized gingival width. The period of performance runs from September 14, 2026 to September 9, 2027, with work performed in Milwaukee, Wisconsin 53233. The source identifies no sub-recipients.
Description
- Abstract
- This proposal addresses a critical need in periodontal care by developing a novel, cost-effective product called mucoregen for gingival tissue regeneration. While autologous grafts such as free gingival grafts (FGG) and connective tissue grafts (CTG) are considered the gold standard for treating gingival loss, they are invasive and associated with donor site morbidity. Commercial alternatives such as mucograft®, alloderm®, and novomatrix® offer effective outcomes but are excessively expensive and limited in their ability to replicate the elasticity and structure of native gingiva. Mucoregen addresses these limitations by utilizing a novel gelatin-based matrix enhanced with other safe, natural and biodegradable materials to create a biomimetic and affordable alternative. To the best of our knowledge, no gelatin-based matrix is currently available on the market for gingival regeneration. The formulation proposed for mucoregen has been extensively optimized by the PI's research group. The innovation of mucoregen comes not only from its material composition but also from its novel fabrication method, that creates a dual-porosity scaffold with interconnected macro- and micropores that closely mimic native extracellular matrix. This architecture enhances nutrient diffusion, cell infiltration, and proliferation. Our in vitro studies have demonstrated over a threefold increase in cell proliferation compared to conventional scaffolds. Preliminary and pilot in vivo studies showed that mucoregen performs comparably to autologous grafts and slightly greater than mucograft® (a widely used collagen-based commercial product) in increasing keratinized gingival width. In this study, mucoregen supported both ortho- and para-keratinization and demonstrates promising histological outcomes, including organized collagen deposition and vascularization. The proposed phase I study will include comprehensive in vitro and in vivo evaluations, comparing mucoregen with allografts and various commercially available products-including mucograft®, alloderm®, and novomatrixtm-to validate its performance. In our study design, FGG represents the gold-standard autograft, alloderm® is a human acellular dermal matrix (ALLOGRAFT), mucograft® is a collagen-based XENOGRAFT, and novomatrixtm is an animal acellular dermal matrix (XENOGRAFT), thus covering all major graft categories. While the cost of commercial products ranges from $250 to $800, the projected cost of mucoregen is under $100, primarily due to the use of an optimized composition of lower-cost materials. With the soft tissue regeneration market growing at a compound annual growth rate (CAGR) of 7.8%, driven by the increasing prevalence of periodontal diseases and rising demand for aesthetic dental treatments, soft tissue graft revenue alone is expected to reach $2.11 billion by 2034. This growth presents strong commercial potential for a low-cost and effective alternative. Mucoregen could help reduce healthcare costs, increase access to periodontal treatments, and improve clinical outcomes in both functional and esthetic dentistry.
Quick answers
Who received award R41DE035779?
R41DE035779 was awarded to Preserver TECH LLC by National Institute of Dental and Craniofacial Research (National Institutes of Health) on September 14, 2026.
How much is award R41DE035779 worth?
$306,872 has been obligated on R41DE035779.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award